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1Background and Purpose—We aimed to determine the safety and mortality after mechanical thrombectomy in patients 
taking vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs).
Methods—In a multicenter observational cohort study, we used multiple logistic regression analysis to evaluate associations 
of symptomatic intracranial hemorrhage (sICH) with VKA or DOAC prescription before thrombectomy as compared 
with no anticoagulation. The primary outcomes were the rate of sICH and all-cause mortality at 90 days, incorporating 
sensitivity analysis regarding confirmed therapeutic anticoagulation. Additionally, we performed a systematic review and 
meta-analysis of literature on this topic.
Results—Altogether, 1932 patients were included (VKA, n=222; DOAC, n=98; no anticoagulation, n=1612); median 
age, 74 years (interquartile range, 62–82); 49.6% women. VKA prescription was associated with increased odds for 
sICH and mortality (adjusted odds ratio [aOR], 2.55 [95% CI, 1.35–4.84] and 1.64 [95% CI, 1.09–2.47]) as compared 
with the control group, whereas no association with DOAC intake was observed (aOR, 0.98 [95% CI, 0.29–3.35] 
and 1.35 [95% CI, 0.72–2.53]). Sensitivity analyses considering only patients within the confirmed therapeutic 
anticoagulation range did not alter the findings. A study-level meta-analysis incorporating data from 7462 patients 
(855 VKAs, 318 DOACs, and 6289 controls) from 15 observational cohorts corroborated these observations, yielding 
an increased rate of sICH in VKA patients (aOR, 1.62 [95% CI, 1.22–2.17]) but not in DOAC patients (aOR, 1.03 
[95% CI, 0.60–1.80]).
Conclusions—Patients taking VKA have an increased risk of sICH and mortality after mechanical thrombectomy. The lower 
risk of sICH associated with DOAC may also be noticeable in the acute setting. Improved selection might be advisable 
in VKA-treated patients.
Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT03496064. Systematic Review and Meta-
Analysis: CRD42019127464.   (Stroke. 2020;51:00-00. DOI: 10.1161/STROKEAHA.119.026606.)
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Symptomatic intracranial hemorrhage (sICH) is a dreaded complication in patients with an acute ischemic stroke 
(AIS) treated with intravenous thrombolysis (IVT) or endo-
vascular therapy (EVT). The overall risk of sICH in patients 
receiving mechanical thrombectomy (MT) in 5 large random-
ized controlled trials was 4.4%.1
Therapeutic oral anticoagulation (OAC) was a prominent 
risk factor for hemorrhagic complications in unselected AIS 
patients2; however, the relative increase in risk in patients tak-
ing OAC who undergo MT is unknown. Patients on antico-
agulants were often excluded from recent pivotal randomized 
controlled MT trials, and subgroup analysis of patients on 
OAC is lacking. Data on efficacy and safety of endovascu-
lar treatment in patients on anticoagulants, especially those 
on direct OACs (DOACs), are hence scarce and observational 
(Table I in the online-only Data Supplement).3–17 Additionally, 
most studies did not differentiate between therapeutic and 
nontherapeutic activity of OAC.
Therefore, the main objectives of this study were (1) to de-
termine the risk of sICH and mortality in MT patients taking 
either vitamin K antagonists (VKAs) or DOAC as compared 
with patients without OAC in a large multicenter registry; (2) 
to provide a sensitivity analysis including only patients with 
confirmed therapeutic anticoagulation activity; and (3) to pre-
sent an up-to-date meta-analysis summarizing the available 
observational evidence of sICH and mortality risk in patients 
undergoing endovascular recanalization procedures.
Methods
Data Availability Statement
The deidentified data generated and analyzed in this study will be 
available and shared on request from any qualified investigator for 
the purposes of replicating procedures and results, after clearance by 
the ethics committee.
Observational Cohort Study
The study protocol of the BEYOND-SWIFT registry has been regis-
tered (NCT03496064), and details have been published previously.18 
In brief, the registry is a retrospective, international, multicenter, 
nonrandomized observational study set up to investigate the safety 
and efficacy of a market-release neurothrombectomy device (applied 
as initial devices) in AIS patients. Table II in the online-only Data 
Supplement gives an overview of the patients included, availability 
of follow-up data for each center, and ethical approval procedure.
For the primary analysis, we included all patients from BEYOND-
SWIFT (Bernese-European Registry for Ischemic Stroke Patients 
Treated Outside Current Guidelines With Neurothrombectomy 
Devices Using the Solitaire FR With the Intention for Thrombectomy) 
for whom information on OAC therapy before stroke onset was avail-
able. We grouped patients according to their intake of anticoagu-
lants before admission: VKA (group 1) and DOAC therapy (group 
2) were defined as patients with a current prescription for a VKA 
or DOAC drug at the time of symptom onset. Patients without OAC 
(group 3) were defined as those with no current prescription of an 
OAC substance at the time of symptom onset. Intake of antiplate-
let therapy did not affect assignment to a group. For the sensitivity 
analysis, we defined confirmed therapeutic anticoagulation as an in-
ternational normalized ratio (INR) >1.7 in patients taking VKA or 
specific drug activity >50 ng/mL19–23 in patients taking DOAC. If no 
specific drug activity measurement was available in patients taking 
DOAC, confirmed therapeutic OAC was defined as either (1) drug 
intake within the last 24/12 hours for once daily/twice daily medica-
tion; (2) thrombin time >38 seconds in patients taking dabigatran24; or 
(3) INR >1.2 in patients taking Xa inhibitors (apixaban, edoxaban, or 
rivaroxaban; Table III in the online-only Data Supplement).25,26
Variables and Image Analysis
Local investigators collected data on OAC medication before stroke 
onset and records of coagulation assays, which were performed 
according to local standards. We defined tandem occlusion as the 
presence of an intracranial large vessel occlusion and >90% extra-
cranial cervical stenosis or occlusion. We defined successful recan-
alization as reperfusion of at least 50% of the initially occluded 
target territory, according to the modified treatment in cerebral is-
chemia score (≥2b).27
Outcomes
The primary end point of this analysis was sICH until hospital dis-
charge, which was assessed at each center applying the ECASS II 
(European Co-Operative Acute Stroke Study-II) criteria.28 Secondary 
outcomes were technical efficacy and all-cause mortality at 3 months. 
For evaluation of the functional outcome at 3 months, we applied the 
modified Rankin Scale obtained during routinely scheduled clinical 
visits or standardized telephone interviews. We present the rates of 
good functional outcome (modified Rankin Scale score, 0–2).
Statistical Analysis
We compared the 3 groups (VKA, DOAC, and patients without 
OAC) and the 2 OAC groups (VKA versus DOAC; Table IV in the 
online-only Data Supplement) using appropriate statistical meas-
ures (χ2 test for categorical variables, Kruskal-Wallis H test for non-
normally continuous or ordinally scaled variables, and ANOVA for 
independent, normally distributed data, Fisher exact test for catego-
rical variables, Mann-Whitney U test for non-normally continuous 
or ordinally scaled variables, and Welch t test for independent, nor-
mally distributed data).
For the analysis of a preinterventional model, the association of OAC 
type with the binary outcome parameter was assessed separately for 
each outcome (primary outcome sICH or mortality or good functional 
outcome) using multiple logistic regression controlling for the following 
prespecified confounders: age (continuous), sex (categorical), National 
Institutes of Health Stroke Scale on admission (ordinal, adjusted odds 
ratio [aOR] per point increase), hypertension (categorical), diabetes 
mellitus (categorical), dyslipidemia (categorical), cardioembolic stroke 
subtype (categorical), time from symptom onset to groin puncture (con-
tinuous), type of imaging (categorical), tandem occlusion (categorical), 
and IVT (categorical). The rationale for this model was the combination 
of known predictors of sICH following EVT29–34 and baseline differ-
ences between patients experiencing sICH and those who did not (Table 
V in the online-only Data Supplement). Patients with missing data items 
were excluded from the multivariable analysis. For the sensitivity anal-
ysis, the same model was used to assess the association of INR (contin-
uous) with sICH in VKA patients. No corrections for multiple testing 
were made for secondary and sensitivity analyses.
For the prognostic postinterventional model, the following ad-
ditional confounders were included: reperfusion success (catego-
rical), use of balloon guide catheter (categorical), maneuver count 
(ordinal, aOR per one maneuver), time from groin puncture to re-
perfusion (continuous), and compound complication (categorical). 
The rationale for this model was the combination of known pre-
dictors of sICH following EVT29–34 and interventional differences 
between patients with sICH and without sICH (Table IV in the 
online-only Data Supplement).
Systematic Review and Meta-Analysis
We performed a systematic review and meta-analysis conforming 
to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement35 and the Meta-Analysis of Observational Studies 
in Epidemiology checklist36 (for further details, search strategy, and 
statistics, see the online-only Data Supplement). The systematic re-
view and meta-analysis was registered at the International Prospective 
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Register of Systematic Reviews (CRD42019127464). Briefly, preva-
lences of sICH and mortality in patients undergoing EVT according 
to whether patients had previously been prescribed DOAC, VKA, or 
no OAC were used to calculate summary estimates of effect sizes 
(summarized odds ratios [sORs])37 using the inverse variance heter-
ogeneity model assuming heterogeneous populations and accounting 
for multiple true effect sizes. When information was missing in the 
original publication, we contacted the lead authors to request the ad-
ditional information. We display summarized point estimates together 
with the corresponding 95% CIs to express the odds for a comparison 
between VKA or DOAC and patients without OAC.
Standard Protocol Approvals, Registrations,  
and Patient Consents
Ethical approval was granted by local ethical standards committees 
(see Table II in the online-only Data Supplement for details of each 
center). Additionally, ethical approval was obtained for centrally 
pooling the data in Bern (KEK Bern, Bern, Switzerland, Local Ethics 
Committee study identifier: 2018-00766). The registry is registered 
at https://www.clinicaltrials.gov (NCT03496064) and the systematic 
review and meta-analysis at the Prospective Register of Systematic 
Reviews (CRD42019127464).
Results
Baseline
For 1942 of 2046 patients in the registry, information on OAC 
medication was available (222 VKAs, 98 DOACs, and 1622 no 
OAC) hence excluding 104 patients for whom information on 
OAC medication was missing. For 317 of 320 (99.1%) patients 
on OAC, information on sICH was available, and 267 of 320 
(83.4%) had documented 90-day follow-up. INR was available 
for 138 of 222 (62.2%) patients taking VKA. Information on 
DOAC compliance was available for 35 of 98 (36%) patients 
(23, medication certainly taken; 12, certainly not taken; 63, not 
documented). Reliable assessments of DOAC activity were avail-
able for 44 of 98 (45%) patients. Either documented information 
on compliance or a reliable assessment of DOAC activity was 
available for 70 of 98 (71%) patients. Altogether, 1596 of 1942 
(82.2%) patients were included in the primary multiple regres-
sion analysis (Figure I in the online-only Data Supplement). The 
main data item missing was a record of symptom to groin time 
(258/1942); other missing items concerned <2% of patients.
Baseline characteristics and univariable comparisons of 
patients according to OAC status before AIS are presented in 
Table IV in the online-only Data Supplement.
Characteristics and univariable comparisons of patients 
experiencing sICH and those not experiencing sICH after MT 
are presented in Table V in the online-only Data Supplement. 
Patients who had an sICH were more often on OAC, under-
went magnetic resonance imaging as the initial imaging mo-
dality less often, and more often had a more proximal large 
vessel occlusion. Furthermore, there was a trend toward 
higher baseline National Institutes of Health Stroke Scale and 
tandem occlusions in patients with an sICH.
Univariable Analysis
Univariable outcomes are presented in the Table. Univariable 
logistic regression analysis showed that VKA significantly 
increased the odds of sICH (aOR, 1.920 [95% CI, 1.164–
3.166]) and mortality (aOR, 1.680 [95% CI, 1.212–2.327]) 
compared with patients not receiving OAC (Table VI in the 
online-only Data Supplement). No significant associations 
regarding sICH (aOR, 0.989 [95% CI, 0.391–2.497]) and 
mortality (aOR, 1.482 [95% CI, 0.871–2.523]) were found 
for DOAC patients when compared with patients not re-
ceiving OAC.
Preinterventional Model
According to the preinterventional multiple logistic regression 
analysis, after adjusting for prespecified confounders, VKA 
therapy was associated with increased odds for sICH and mor-
tality (aOR, 2.554 [95% CI, 1.349–4.836] and 1.639 [95% CI, 
1.086–2.473], respectively) compared with the control group, 
whereas DOAC therapy showed no significant associations 
with either (aOR, 0.982 [95% CI, 0.288–3.346] and 1.351 
[95% CI, 0.722–2.527]). Of the prespecified confounders, IVT 
(aOR, 1.648 [95% CI, 1.015–2.677]) and tandem occlusion 
(aOR, 1.897 [95% CI, 1.118–3.218]) were associated with 
sICH (Table VII in the online-only Data Supplement). When 
considering only patients previously prescribed VKA, the 
INR on admission was not associated with sICH occurrence 
(aOR, 0.770 [95% CI, 0.206–2.883] per 1.0 increase). Those 
results were consistent in propensity score matching and near-
est-neighbor matching (online-only Data Supplement).
In the sensitivity analysis considering only patients with 
confirmed therapeutic VKA therapy, the point estimate for sICH 
was similar to that for control patients although not statistically 
significant (aOR, 2.314 [95% CI, 0.831–6.443]). Confirmed 
therapeutic VKA therapy was associated with higher mortality 
(aOR, 1.969 [95% CI, 1.058–3.665]). Comparison of patients 
on confirmed therapeutic DOAC with controls showed a trend 
toward higher mortality (aOR, 2.044 [95% CI, 0.916–4.561]). 
For patients on therapeutic DOAC, no point estimate could be 
calculated for sICH owing to the low incidence of the outcome. 
Characteristics of patients with and without missing values in the 
primary analysis of the multivariable preinterventional model 
are presented in Table VIII in the online-only Data Supplement. 
DOAC patients had fewer missing data items, but no univariable 
predictor of sICH was significantly different between patients 
with and those without missing data items.
Postinterventional Model
Also in the postinterventional multiple regression model 
adjusting for additional interventional confounders, VKA 
therapy significantly increased the odds of sICH compared 
with patients not receiving OAC (aOR, 2.553 [95% CI, 
1.034–6.301]). VKA therapy approached significance to 
increase the odds of all-cause mortality at day 90 as com-
pared with patients without OAC (aOR, 1.697 [95% CI, 
0.992–2.904]). No statistically significant associations were 
found between DOAC and sICH (aOR, 0.715 [95% CI, 
0.088–5.806]) or DOAC and mortality (aOR, 1.565 [95% 
CI, 0.710–3.451]) as compared with patients without OAC. 
Of the confounders, the National Institutes of Health Stroke 
Scale on admission (aOR, 1.041 [95% CI, 1.001–1.083]) and 
occurrence of complications (aOR, 3.467 [95% CI, 1.753–
6.854]) were associated with sICH (Table IX in the online-
only Data Supplement).
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Technical Efficacy
The rate of successful reperfusion was higher in DOAC patients 
(93.2%; Table X in the online-only Data Supplement) than VKA 
patients (81.5%), although the rate of excellent reperfusion was 
similar. The procedure duration was shorter in DOAC patients, 
and general anesthesia was less often used. Extracranial stenting 
was more often performed in patients not receiving OAC.
Functional Outcome
Patients on VKA had lower rates of good functional outcome 
at 3 months than patients who did not receive OAC in the uni-
variable analysis, although the differences were nonsignificant 
in the multivariable analysis. No significant difference in func-
tional outcome, either in univariable or multivariable analysis, 
was found between patients on DOAC and those who were not 
on OAC (Table; Table VI in the online-only Data Supplement).
Meta-Analysis
The database searches and citation tracking yielded 751 hits. 
After removing duplicates, 381 abstracts and 45 full-text 
records were screened as potentially relevant. In total, 14 pub-
lications met the inclusion criteria of reporting the risk of sICH 
after EVT for large vessel occlusion in AIS patients with OAC 
pretreatment and inclusion of a control group receiving no OAC 
(13 for VKA and 10 for DOAC; Figure II in the online-only 
Data Supplement). The definitions of sICH and comparator 
groups across studies were somewhat heterogeneous (Table I 
in the online-only Data Supplement). We included a total of 
855 VKA cases, 318 DOAC cases, and 6289 controls in the 
meta-analysis. Pooled analysis of these studies showed a signif-
icant difference in sICH rate (sOR, 1.62 [95% CI, 1.22–2.17]) 
and mortality rate (sOR, 1.66 [95% CI, 1.28–2.15]) between 
patients on VKA undergoing EVT and patients in the com-
parator groups (Figure; Figures III and IV in the online-only 
Data Supplement). No such difference was observed for DOAC 
patients as compared with the control groups for either sICH 
(sOR, 1.03 [95% CI 0.60–1.80]) or mortality (sOR, 1.35 [95% 
CI, 0.97–1.87]). There was no signal of either pronounced 
heterogeneity (I2 sICH for VKA, 11%; Cochrans Q, 13.5; df, 
12; χ2; P=0.33) or of publication bias (funnel plot, Figures V 
through IX in the online-only Data Supplement).
Discussion
The main findings of this registry study and meta-analysis of 
endovascular treatment in patients with preceding OAC treat-
ment were as follows:
(1) Patients on VKA, but not DOAC, had an increased risk 
of sICH after MT (aOR, 2.55 [95% CI, 1.35–4.84]) compared 
with patients not on OAC in our registry; (2) the meta-analysis 
incorporating data from a total of 7462 patients (855 VKAs, 318 
Table. Outcome Data Comparing Patients According to Status of Oral Anticoagulation on Univariable χ2 Analysis
Outcome DOAC (n=98) VKA (n=222) Other (n=1622) P Value
P for All DOACs 
vs All VKAs
Warranted 
Therapeutic 
DOAC (n=49)
Warranted 
Therapeutic VKA 
(n=69)
P for Therapeutic 
DOAC vs 
Therapeutic VKA
sICH ECASS II 5 (5.2%) 21 (9.5%) 84 (5.2%) 0.033 0.267 2 (4.2%) 5 (7.4%) 0.698
Mortality at 3 mo 21 (31.8%) 64 (34.6%) 347 (23.9%) 0.004 0.763 15 (42.9%) 21 (35.0%) 0.513
Systemic bleeding 0 (0%) 6 (6.5%) 22 (3.4%) 0.287 0.408 0 (0%) 2 (5.3%) 1.000
mRS 0–2 at 3 mo 29 (43.9%) 61 (33%) 648 (44.7%) 0.010 0.135 16 (45.7%) 21 (35.0%) 0.384
DOAC indicates direct oral anticoagulant; mRS, modified Rankin Scale; sICH ECASS II, symptomatic intracranial hemorrhage according to the European Co-Operative 
Acute Stroke Study-II definition; and VKA, vitamin K antagonist.
Figure. Meta-analysis of risk of symptomatic intracranial hemorrhage of patients with anticoagulation as compared to controls.38–43 Forest plot of unadjusted 
odds ratios for symptomatic intracranial hemorrhage in patients on vitamin K antagonist (VKA; A) and direct oral anticoagulant (DOAC; B) as compared with 
patients not on anticoagulation. IV indicates inverse variance. 
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DOACs, and 6289 controls) corroborated this observation, sug-
gesting that only preceding VKA treatment increases the risk 
of sICH after endovascular procedures (aOR, 1.62 [95% CI, 
1.22–2.17]); (3) in both the registry and meta-analysis, the mor-
tality was higher in patients on OAC than in controls, although 
statistical significance was only reached in VKA patients; (4) 
endovascular procedures were feasible and technically success-
ful in a similar proportion of OAC patients to that in controls; 
and (5) even in tertiary stroke centers, the assessment of com-
pliance and laboratory diagnosis of OAC activity is inadequate.
In our registry, the overall rate of OAC pretreatment in MT 
patients was 16%, similar to published data,15 emphasizing the 
importance of this clinical situation.44 Generally, therapeutic 
OAC is a prominent risk factor for hemorrhagic complications in 
AIS patients.2 However, several studies with small patient num-
bers failed to show a significant association of OAC with sICH 
in the subcohort of patients undergoing EVT for AIS (Table I in 
the online-only Data Supplement). Most of the studies focusing 
on EVT, however, were limited by different rates of IVT, inclu-
sion of patients with subtherapeutic INR, missing information on 
OAC reversal before MT, and lack of adjustment for comorbidi-
ties. Despite the pathophysiological plausibility of an increased 
risk of sICH after EVT in OAC cohorts, those limitations might 
explain the lack of a significant association in previous observa-
tional cohort studies. Both our pooled registry analysis and the 
meta-analysis provided evidence for an increased risk of sICH in 
VKA patients but not DOAC patients. Our findings of a roughly 
halved risk of sICH in patients on DOAC as compared with those 
on VKA after acute recanalization are comparable to the benefits 
of a lower sICH risk in patients on DOAC observed in random-
ized controlled trials and real-world data on stroke prevention.45–47
Despite an increased risk of sICH, we do not think that this 
possible downside outweighs the pronounced benefit of MT in 
patients on VKA with a large vessel occlusion. Nevertheless, 
this finding has several clinical implications. First, when clinical 
deterioration occurs after MT, sICH should be suspected with 
an even lower threshold in patients on VKA than on DOAC or 
patients not receiving OAC. Second, imaging features should be 
investigated to identify VKA patients susceptible to sICH. Third, 
future studies need to clarify whether there is an INR cutoff at 
which there is a deleterious effect of performing MT in VKA 
patients. Fourth, further research needs to address the question 
whether reversal strategies for selected VKA patients undergoing 
MT could prevent the occurrence of sICH or if the administra-
tion of a procoagulant in the setting of an acute thromboembolic 
event actually carries deleterious effects outweighing the po-
tential benefits. Lastly, it presents an additional reason to start 
DOAC treatment rather than VKA in patients newly diagnosed 
with atrial fibrillation. Since therapeutic OAC is a contraindica-
tion for IVT, the finding that, overall, MT was feasible, with a 
similar risk of periprocedural complications, is reassuring.
Despite neither being designed nor powered to address 
mortality, the point estimates of our analysis indicating an 
increase in 3-month mortality in patients who had had VKA 
treatment as compared with patients not on OAC are in line 
with previously published results.6,9,10,14,17,48 The increased 
occurrence of sICH might partially explain this observation. 
However, patients on DOAC also showed a trend toward 
increased mortality reflecting the overall worse prognostic 
profile of patients on OAC as compared with controls (Table 
IV in the online-only Data Supplement), inherent to indica-
tions that led OAC to be prescribed in the first place.
Corroborating previous studies indicating good technical 
efficacy and feasibility of EVT in OAC patients, we observed 
comparable rates of successful reperfusion and no excess of 
periprocedural complications other than sICH. Interestingly, 
the rates of successful reperfusion were only higher in the 
DOAC group as compared with the no OAC and VKA groups, 
potentially reflecting differences in thrombus formation. In 
our registry, the time from onset of symptoms to recanaliza-
tion was similar to that reported by other authors,14,15 without 
any delay in OAC patients.
In our study, the therapy was proven to be in the ther-
apeutic range in only 50% of patients on VKA and 72% 
of those on DOAC. This has potentially important reper-
cussions, as patients on therapeutic OAC may present 
with less severe strokes, less frequently show a target ves-
sel occlusion,44,49 and differ in terms of eligibility for IVT. 
Interestingly, this was also observed in our OAC cohort, 
as the rate of IVT was significantly lower in patients with 
confirmed therapeutic anticoagulation (VKA, 5.8% versus 
34.8%, P<0.001; and DOAC, 4.1 % versus 26.3%, P=0.016). 
Those findings highlight the importance of conducting future 
studies that reliably differentiate between therapeutic and 
nontherapeutic OAC in patients prescribed VKA and DOAC 
as those populations may be heterogeneous.
We did not observe any dose dependency of anticoagulant 
activity in regard to sICH in VKA patients; in fact, the rate of 
sICH was lower when the INR was within the therapeutic range. 
However, there are important reasons for this paradoxical ob-
servation. First, CIs of sICH in VKA patients with confirmed 
therapeutic anticoagulation (1.1%–13.4%) and without (5.6%–
13.3%) were wide, and the finding that INR was not significantly 
associated with sICH might have been underpowered. Second, 
stroke is less severe in patients on therapeutic VKA,50 which 
in turn reduces the risk of sICH. Lastly, and most importantly, 
IVT was used more often in subtherapeutic patients, potentially 
increasing the risk of sICH in this subgroup and possibly obscur-
ing the dose dependency. The data on the association of IVT 
with sICH in the setting of EVT, however, are inconclusive.51
Strengths and Limitations
Because of the large sample size and good quality of the data, we 
were able to include many pre- and postinterventional confound-
ers in our model. Despite this potential overadjustment, the as-
sociation of VKA pretreatment with sICH remained statistically 
significant, arguing for a real effect. Nevertheless, this study has 
the known limitations of a single-arm multicenter retrospective 
registry. Most importantly, patient selection for MT was not speci-
fied, was center specific, and no medical comparison group was 
available. We had no information on several predictors that were 
shown to be associated with sICH after IVT including micro-
bleeds,52 white matter disease,53 and glycated hemoglobin A1c.54 
The date of intervention was not known, and patients on DOAC 
might have been treated somewhat more recently on average due 
to the change from VKA to DOAC. However, there were no major 
improvements in stroke care to avoid sICH in this period, and ex-
pansion of indications for MT (eg, more distal occlusions) might 
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have increased the risk of sICH lately. Finally, it remains possible 
that the choice of VKA over DOAC might represent a surrogate 
marker of other residual confounding variables not recorded in 
the registry (renal function, malignancy, frailty, mechanical heart 
valves, etc) representing the true reason for increased risk for 
sICH in VKA patients. The studies included in the meta-analysis 
represent populations with heterogeneous use of IVT and different 
proportions of IVT use in patients on OAC versus patients not on 
OAC, as well as different combinations of intraarterial thromboly-
sis and MT and use of first-generation devices.
Conclusions
EVT patients who have received VKA therapy have an 
increased risk of sICH, while no excess risk was observable 
for patients on DOAC therapy, potentially reflecting the ben-
efits of a lower sICH risk of DOAC observed in stroke preven-
tion. In VKA patients undergoing EVT, increased awareness 
is advisable when clinical deterioration occurs after the pro-
cedure. Nevertheless, MT should be performed in most VKA 
patients with a target large vessel occlusion after a careful 
risk-benefit evaluation considering the potentially salvageable 
tissue. Efforts should be made to routinely assess compliance 
and obtain adequate laboratory diagnosis of the OAC status in 
patients on VKA and DOAC in emergency situations.
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